A Research Study of House Dust Mite (HDM) SLIT-tablet for the Treatment of HDM Allergy in Chinese Participants Aged 12-65

Who May Qualify: - Male or female Chinese subjects aged 12-65 years - A clinical history of HDM AR/C (Allergic rhinitis/rhinoconjunctivitis) (with or without asthma) and with allergic rhinitis symptoms despite having received allergy pharmacotherapy during the previous year prior to screening - Have a certain level of AR (Allergic rhinitis) symptoms on at least 8 of the last 14 days of the baseline period - Use symptomatic medication for treatment of HDM allergic rhinitis during at least 8 of the last 14 days of the baseline period - Positive skin prick test (SPT) and IgE (Immunoglobulin E) to D. pteronyssinus or D. farinae at screening - Lung function ≥ 70% of predicted value Who Should NOT Join This Trial: - Sensitised and regularly exposed to perennial allergens - Any nasal or pharyngeal condition that could interfere with the safety or efficacy evaluation - Asthma requiring treatment with high dose of inhaled corticosteroid - A relevant history of systemic allergic reaction Always talk to your doctor about whether this trial is right for you.